Xavier M Keutgen1, Naris Nilubol1, Joanne Glanville1, Samira M Sadowski1, David J Liewehr2, David J Venzon2, Seth M Steinberg2, Electron Kebebew3. 1. Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kebebewe@mail.nih.gov.
Abstract
BACKGROUND: Nonfunctioning pancreatic neuroendocrine tumors (NFpNET) present with distant metastases in up to 50% of patients. It is unknown whether removal of the primary tumor in patients with NFpNET and metastases is beneficial. METHODS: We used the Surveillance, Epidemiology, and End Results database to identify patients with NFpNET and distant metastases. The primary outcome measure in this study was overall survival. RESULTS: We identified 882 patients with metastatic NFpNET who had survival data; 303 (34%) patients had operative removal of their primary tumor of which 243 (80%) were grade I or II. Median survival of patients undergoing resection of the primary site was 65 (95% confidence interval 60-86) versus 10 (8-12) months for those without resection (P < .0001). Patients diagnosed after 2003 (n = 625, 71%) were more likely to undergo an operation than those diagnosed earlier (P = .001). Multivariable analysis showed that a lesser tumor grade (P < .0001), younger age (P < .0001), diagnosis during or after 2003 (P = .0003), tumor site in the body/tail (P = .009), and operative resection of the primary tumor site (P < .0001) were associated with prolonged survival of patients with NFpNET and distant metastases. CONCLUSION: This study suggests that resection of the site of the primary NFpNET is associated with greater survival in patients with distant metastases and could therefore be considered as a additional treatment option in this patient population. Published by Elsevier Inc.
BACKGROUND: Nonfunctioning pancreatic neuroendocrine tumors (NFpNET) present with distant metastases in up to 50% of patients. It is unknown whether removal of the primary tumor in patients with NFpNET and metastases is beneficial. METHODS: We used the Surveillance, Epidemiology, and End Results database to identify patients with NFpNET and distant metastases. The primary outcome measure in this study was overall survival. RESULTS: We identified 882 patients with metastatic NFpNET who had survival data; 303 (34%) patients had operative removal of their primary tumor of which 243 (80%) were grade I or II. Median survival of patients undergoing resection of the primary site was 65 (95% confidence interval 60-86) versus 10 (8-12) months for those without resection (P < .0001). Patients diagnosed after 2003 (n = 625, 71%) were more likely to undergo an operation than those diagnosed earlier (P = .001). Multivariable analysis showed that a lesser tumor grade (P < .0001), younger age (P < .0001), diagnosis during or after 2003 (P = .0003), tumor site in the body/tail (P = .009), and operative resection of the primary tumor site (P < .0001) were associated with prolonged survival of patients with NFpNET and distant metastases. CONCLUSION: This study suggests that resection of the site of the primary NFpNET is associated with greater survival in patients with distant metastases and could therefore be considered as a additional treatment option in this patient population. Published by Elsevier Inc.
Authors: Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914
Authors: Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng Journal: Cancer Date: 2009-02-15 Impact factor: 6.860
Authors: James T McPhee; Joshua S Hill; Giles F Whalen; Maksim Zayaruzny; Demetrius E Litwin; Mary E Sullivan; Frederick A Anderson; Jennifer F Tseng Journal: Ann Surg Date: 2007-08 Impact factor: 12.969
Authors: R Bettini; W Mantovani; L Boninsegna; S Crippa; P Capelli; C Bassi; A Scarpa; P Pederzoli; M Falconi Journal: Dig Liver Dis Date: 2008-05-07 Impact factor: 4.088
Authors: G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann Journal: Virchows Arch Date: 2006-09-12 Impact factor: 4.064
Authors: James C Yao; Milton P Eisner; Colleen Leary; Cecile Dagohoy; Alexandria Phan; Asif Rashid; Manal Hassan; Douglas B Evans Journal: Ann Surg Oncol Date: 2007-09-26 Impact factor: 5.344
Authors: Yusuf Menda; Thomas M O'Dorisio; James R Howe; Michael Schultz; Joseph S Dillon; David Dick; G Leonard Watkins; Timothy Ginader; David L Bushnell; John J Sunderland; Gideon K D Zamba; Michael Graham; M Sue O'Dorisio Journal: J Nucl Med Date: 2017-02-02 Impact factor: 10.057
Authors: James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier Journal: Pancreas Date: 2020-01 Impact factor: 3.327
Authors: Sarah R Kaslow; Gerardo A Vitiello; Katherine Prendergast; Leena Hani; Steven M Cohen; Christopher Wolfgang; Russell S Berman; Ann Y Lee; Camilo Correa-Gallego Journal: Ann Surg Oncol Date: 2022-03-05 Impact factor: 5.344
Authors: Derya Kıvrak Salim; Selami Bayram; İsmail Gömceli; Ayhan Hilmi Çekin; Mustafa Karaca; Murat Koçer; Mustafa Yıldız Journal: Turk J Gastroenterol Date: 2019-10 Impact factor: 1.852